Skip to content
DraconiticResearch
Search Sources API
197,785 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Tumor tagging: making cold tumors visible to immunotherapy

  • Tong-Yun Wang1,2
  • Yue Sun2
  • Feng Cong1,2,3
  • Yan-Dong Tang2
  1. 1College of Animal Science and Technology, Zhongkai University of Agriculture and Engineering, Guangdong Engineering Technology Research Center of Biosafety and Intelligent Control for Aquatic Animals Diseases
  2. 2State Key Laboratory of Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences
  3. 3Guangdong Hengqin Newcastle disease virus (NDV) Biotechnology Co., Ltd.
Read full textDOICite

Abstract

Cold tumors are poorly recognized by host immunity. Tumor tagging strategies—neoantigen, xenogeneic, and viral antigen tagging—endow tumor cells with identifiable antigens via engineered probiotics, oncolytic viruses, and mRNA delivery. These tactics yield compelling preclinical and clinical results, emerging as a novel promising strategy for cancer immunotherapy.

Related

  1. Systemic tumor-cell reprogramming converts solid tumors into in situ biofactories for immunotherapy
    S. Wang, Q. Xu, M. Wu +5
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  2. 1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
    Justin Moser, Igor Puzanov, Hans Hammers +15
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. Making Generative AI Use Visible in a Foundational Health-Sciences Course: Effects on Learning, Verification and Attribution
    Xinhui Li
    Medical Science EducatorPeer-reviewedLicence not statedFull textEpidemiology & public healthPMC
  4. Editorial: Chemoresistance and immunotherapy in solid tumors
    Junchao Xu
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  5. Beyond the TCDD Lens in Paritutu/New Plymouth, New Zealand: Invisible Phenoxy-Herbicide Co-Contaminants, Visible Developmental Signals, and Decision-Making under Incomplete Evidence
    Andrew Gibbs
    Pollution and DiseasesPeer-reviewedCC BY8 citedPharmacology & toxicologyOpenAlex

Cite

BibTeXRIS
BibTeX
@article{wang2026tumor,
  title = {{Tumor tagging: making cold tumors visible to immunotherapy}},
  author = {Tong-Yun Wang and Yue Sun and Feng Cong and Yan-Dong Tang},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1981961},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1981961/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Tumor tagging: making cold tumors visible to immunotherapy
AU  - Tong-Yun Wang
AU  - Yue Sun
AU  - Feng Cong
AU  - Yan-Dong Tang
PY  - 2026
DA  - 2026/10/28
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1981961
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1981961/full
AB  - Cold tumors are poorly recognized by host immunity. Tumor tagging strategies—neoantigen, xenogeneic, and viral antigen tagging—endow tumor cells with identifiable antigens via engineered probiotics, oncolytic viruses, and mRNA delivery. These tactics yield compelling preclinical and clinical results, emerging as a novel promising strategy for cancer immunotherapy.
SN  - 1664-3224
ER  -